SpyGlass Pharma (SGP) Enterprise Value (2026)
SpyGlass Pharma (SGP) posted quarterly Enterprise Value of -$107.4 million for Q4 2025, down 560.41% year-over-year from $23.3 million in Q4 2024, and down 560.41% quarter-over-quarter from -$16.3 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Enterprise Value (2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Enterprise Value for 2 consecutive years, with -$107.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value fell 560.41% year-over-year to -$107.4 million; the TTM figure through Dec 2025 stood at -$107.4 million (down 560.41% YoY), while the FY2025 annual figure was -$107.4 million, down 560.41% from the prior year.
- Enterprise Value retreated to -$107.4 million in Q4 2025 per SGP's latest filing, from -$16.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$16.3 million in Q4 2024 and bottomed at -$107.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | SpyGlass Pharma | 973.76 Mn | 973.76 Mn | - |